Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the official account homepage to get the latest trends and expert insights in the digital healthcare industry第一时间!
01 Global Digital Health Investment and Financing OverviewAI Pharmaceutical Company Enveda Raises $150 Million in Series C FundingOn February 26, biotech company Enveda secured $150 million in Series C financing, led by Sanofi. Enveda leverages an AI-driven drug discovery platform, focusing on discovering better drugs from the chemistry of life. The company has advanced ENV-294 into the clinical trial stage. This round of funding will be used to expand its clinical pipeline, enhance AI-driven discovery capabilities, and propel metabolite-driven drug development into a new era.OrganOx, an organ preservation device company, secures $142 million in equity financingOn February 25, medical device company OrganOx secured $142 million in equity financing, led by HealthQuest Capital, with participation from existing investors BGF and Lauxera Capital Partners, as well as new investors Sofina, Soleus Capital, and Avidity Partners. The funds will accelerate the global expansion of OrganOx's Metra platform in the high-growth organ technology market.Medical Artificial Intelligence Technology Researcher OpenEvidence Secures Over $100 Million in Series A FundingOn February 21, OpenEvidence, a medical artificial intelligence technology research company, secured over $100 million in Series A funding, led by Sequoia Capital. OpenEvidence is an AI medical research aggregation platform for doctors, providing free AI medical assistants to physicians in the U.S. By consolidating and synthesizing clinical evidence, it helps doctors make evidence-based decisions.Synthetic Biology Company REDLINE Raises Over 500 Million Yuan in Series C FinancingOn February 22, synthetic biology company REDLINE secured over 500 million yuan in its Series C financing round, jointly invested by Songhe Capital, Cornerstone Capital, and others. The funds will primarily be used for capacity expansion and new product research and development. The company actively applies AI technology to empower the development of synthetic biology products, having built more than 50 AI models and filed nearly 30 AI invention patent applications.Endovascular Engineering, a thrombectomy device company, secures $42 million in Series B fundingOn February 21, Endovascular Engineering, a medical device company specializing in venous thromboembolism (VTE) treatment, secured a $42 million Series B financing round led by 415 Capital and S3 Ventures, with participation from Panakès Partners. The funds will be used to advance its Hēlo PE Thrombectomy System project, which utilizes a patented dual-action mechanism combining powerful suction with mechanical thrombus disruption to enhance the effectiveness of pulmonary embolism (PE) treatment.Neurostimulator Company Valencia Technologies Secures $35 Million in Strategic InvestmentOn February 21, medical device company Valencia Technologies secured a $35 million strategic investment from Brooks Consulting Group, under the Brooks Management Group (BMG), to advance the development of its eCoin neurostimulator device. The device is implanted near the ankle and aims to provide periodic stimulation to the tibial nerve.RNA-Related Biotechnology R&D Company Auron Therapeutics Secures $27 Million in Series B FundingOn February 25, Auron Therapeutics, an RNA-related biotechnology R&D company, secured a $27 million Series B financing round led by DCVC Bio, with participation from Apollo Health Ventures. The company focuses on cellular state plasticity to improve outcomes for patients with cancer and inflammatory diseases. Significant progress has been made in its core projects KAT2A/B and clinical candidate AUTX-703.Brain-Computer Interface Company Motif Neurotech Secures $19 Million in Series A FundingOn February 25, brain-computer interface company Motif Neurotech secured $19 million in Series A funding. The round was led by Arboretum Ventures, with participation from new investors such as KdT Ventures. The funds from the Series A round will be used to advance the development of the DOT microstimulator, a miniature brain pacemaker designed to precisely stimulate the brain and restore healthy neural circuit activity for the treatment of mental illnesses.Ophthalmic Neurostimulation Company Chaomu Technology Secures Over RMB 100 Million in Series B FinancingOn February 26, ophthalmic innovative medical device R&D company ChaoMu Technology secured over 100 million RMB in its Series B funding round, led by Aibot Qing Shi and Fosun Health Capital among others. The company's self-developed Class III active implantable ocular muscle neurostimulator has been submitted for registration. This product is implanted subcutaneously behind the ear and uses a chip system to deliver electrical stimulation to the neuromuscular interface of the extraocular muscles, suppressing abnormal nerve impulses and addressing nystagmus issues.AI Medical Company SenseTime Health Secures Over RMB 100 Million in Pre-A FundingOn February 21, SenseTime Medical, an AI software development company, secured over 100 million yuan in its first round of financing. The round was jointly led by Infore Holdings and People's Health Technology Development Company, an investment platform under the People’s Health Publishing House, with participation from multiple investment institutions. The funds will be used to advance the research and development, implementation, and continued strengthening of commercial partnerships for its large medical model "Dayi" and the comprehensive solution "SenseCare Smart Hospital."OCT Imaging Device Manufacturer Hengyu Medical Secures Over 100 Million Yuan in FinancingOn February 21, Hengyu Medical, an OCT imaging equipment manufacturer, secured over 100 million yuan in financing from New Industry Investment, Huatai Zijin, Beiyang海棠 Fund, Jiuan Medical, and YuanSheng Ventures. This round of financing will be used to promote R&D, production, registration, and accelerate the commercialization process of already listed products.EnPlusOne Biosciences, an RNA-related biotechnology R&D provider, secures $10 million in financingOn February 20, EnPlusOne Biosciences, an RNA-related biotechnology R&D company, secured $10 million in funding led by Northpond Ventures and Breakout Ventures. The funds will be used to expand operations and drive continued technological advancements in its ezRNA™ synthesis platform.Cardiac Disease Treatment Device Developer Berlin Heals Holding AG Secures Over 7 Million Swiss Francs in Series A1 FundingOn February 21, Berlin Heals Holding AG, a developer of cardiac treatment devices, secured an A1 round of financing exceeding 7 million Swiss francs, with participation from both existing and new investors. The proceeds will be used to advance the clinical development of its groundbreaking heart failure treatment device, C-MIC (Cardiac Microcurrent), support the first-in-human studies, and prepare for CE certification and global market entry.Variational AI, a Developer of Artificial Intelligence Drug Discovery Platforms, Secures $5.5M in Oversubscribed FinancingOn February 20, Variational AI, a developer of an artificial intelligence drug discovery platform, secured an oversubscribed $5.5 million financing round led by Nimbus Synergies, with participation from Merck GHI Fund, Quimby Investments, Threshold Impact, Defined Capital, and existing investors Flying Fish, A&E Investment, and Nepenthe Capital. The funding will be used to advance the development of its foundational small-molecule drug discovery model, assisting biopharmaceutical companies in designing new drugs more efficiently.New Gene Therapy Researcher Fuse Vectors Secures $5.2 Million Pre-Seed FundingOn February 25, Fuse Vectors, a novel gene therapy developer, secured a $5.2 million pre-seed funding round led by HCVC. The funds will accelerate the development of its cell-free viral vector technology platform and pipeline of innovative gene therapies.02 Digital Health Industry DynamicsKoios Medical and iCAD Announce Strategic PartnershipOn February 26, Koios Medical and iCAD announced a strategic partnership to jointly showcase an expanded AI-driven multimodal breast cancer detection solution at ECR 2025. This collaboration integrates iCAD’s ProFound AI® Breast Health Suite (for mammography) with Koios’ SmartUltrasound™, providing radiologists with a comprehensive AI-supported pathway from screening to diagnosis. The partnership aims to enhance the efficiency and accuracy of breast cancer screening while streamlining the application of AI technology in mammography and ultrasound.Burning Rock Medical and MGI Tech Reach Strategic CooperationOn February 26, Burning Rock Biotech and MGI Tech reached a strategic cooperation aimed at combining the technical advantages of both parties to promote the research and development of tumor NGS diagnostic products and global business, allowing China's precision diagnosis and treatment solutions to benefit cancer patients worldwide. This cooperation will be based on MGI Tech’s core DNBSEQ sequencing technology, expanding the registration of oncology products and hospital-end business, and jointly advancing the clinical application and globalization of precision oncology treatments. Through technical complementarity and ecosystem co-construction, the two parties will enhance the accessibility and clinical timeliness of tumor NGS testing, further empowering the R&D of oncology diagnostic products. Additionally, the cooperation will accelerate the globalization strategy through a "technology export plus localized cooperation" model, increasing the global influence of Chinese solutions.ZKZDTC and Chengda Biotech Reach Strategic Cooperation Agreement On February 24, ZKZDTT and Chengda Biological signed a strategic cooperation agreement to jointly build an AI life science multimodal large model, aiming to打通the entire chain of life sciences and promote the development of smart healthcare. The collaboration will integrate multimodal data, optimize the vaccine R&D process, improve production efficiency, and help Chengda Biological enter the new era of "AI + vaccines."03 Overview of Global Digital Health M&AGSK, a pharmaceutical R&D manufacturer, acquires IDRx, a clinical-stage biopharmaceutical companyBoston-based clinical-stage biopharmaceutical company IDRx Acquired by Global Leading Drug Development and Manufacturing Giant GSK to Expand Gastrointestinal Stromal Tumor (GIST) Treatment through Precision TherapyIDRx, a company focused on developing innovative therapies for GIST, has shown significant clinical potential with projects like IDRX-42. The total acquisition amount reached up to $1.15 billion, including a $1 billion upfront payment and a possible $150 million in milestone payments. Through this acquisition, GSK will further strengthen its R&D capabilities in the field of oncology treatment and promote the global commercialization process of related drugs.Saintgene Biotech Acquires Zhongshan Weiming Haiji Biomedical Co., Ltd.Sacred Jade Biotech Acquires 100% Equity of Zhongshan Weiming Haiji Biopharmaceutical Co., Ltd. for RMB 807 Million; Zhongshan Weiming Haiji Officially Renamed as Zhongshan Sacred Jade Haiji Biopharmaceutical Co., Ltd., Becoming a Wholly-Owned Subsidiary of Sacred Jade Biotech. This acquisition aims to actively respond to the national call for children's health management, combining Sacred Jade Biotech's advantages in the in vitro diagnostics field with Zhongshan Haiji's expertise in growth hormone, further enhancing the company’s "integrated diagnosis and treatment" comprehensive strategic layout and improving overall profitability.ArteryNet/Arterial Orange Industry Think Tank/China Renaissance/BGI Co-Win/Rock Health/Mobile Health News/FierceHealth, etc.
Compiled by: Liu Shuxia
